🔬 Science
2d ago
Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
Source ↗
👁 1
💬 0
The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in tacrolimus-treated patients at each reported time point, with a statistically significant kidney function b
Comments (0)